clinical trial · NCT05394116
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans ProgressivaGaretosmabPlacebo
brief summary
This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP). The aim of the study is to see how safe and effective the study drug is in patients with FOP. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
started
Nov 21, 2022
primary completion
Jul 17, 2025
completion
Feb 27, 2029
last updated
Jan 16, 2026
official title
Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol